Home Newsfeeds Needham Maintains Buy on Impinj, Raises Price Target to $138

Needham Maintains Buy on Impinj, Raises Price Target to $138

Needham analyst James Ricchiuti maintains Impinj (NASDAQ:PI) with a Buy and raises the price target from $130 to $138.

byBenzinga Newsdesk

February 9, 2023

1 minute read

Needham analyst James Ricchiuti maintains Impinj (NASDAQ:PI) with a Buy and raises the price target from $130 to $138.

Needham Reiterates Buy on Okta, Maintains $90 Price Target

By Benzinga Newsdesk

February 27, 7:58 AM

Needham analyst Alex Henderson reiterates Okta (NASDAQ:OKTA) with a Buy and maintains $90 price target.

OKTA

FTX Liquidations Loom, But Justin Sun Has A Plan

By Murtuza Merchant

September 11, 3:21 PM

In a move to protect the cryptocurrency community from potential market turbulence, Justin Sun, the founder of Tron (CRYPTO: TRON), said Monday he is considering a tender offer for (CRYPTO: TRX)

$FTT

FDA
News

Novavax Announces Initiation Of Phase 2b/3 Hummingbird Global Clinical Trial For Novavax COVID-19 Vaccine In Children Aged Six Months Through 11 Years

By Benzinga Newsdesk

August 4, 9:04 AM

Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of its Phase 2b/3

NVAX

FDA
News

FDA Accepts For Priority Review Ascendis Pharma’s NDA For TransCon™ PTH In Adult Patients With Hypoparathyroidism

By Benzinga Newsdesk

October 31, 8:02 AM

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in adult

ASND

Needham Maintains Buy on Impinj, Raises Price Target to $138

Related Posts

Needham Reiterates Buy on Okta, Maintains $90 Price Target

FTX Liquidations Loom, But Justin Sun Has A Plan

Novavax Announces Initiation Of Phase 2b/3 Hummingbird Global Clinical Trial For Novavax COVID-19 Vaccine In Children Aged Six Months Through 11 Years

FDA Accepts For Priority Review Ascendis Pharma’s NDA For TransCon™ PTH In Adult Patients With Hypoparathyroidism